Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 296

1.

Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis.

Lovelace MD, Varney B, Sundaram G, Franco NF, Ng ML, Pai S, Lim CK, Guillemin GJ, Brew BJ.

Front Immunol. 2016 Aug 4;7:246. doi: 10.3389/fimmu.2016.00246. eCollection 2016. Review.

2.

High-risk coronary plaque, invasive coronary procedures, and cardiac events among HIV-positive individuals and matched controls.

Nadel J, O'Dwyer E, Emmanuel S, Huang J, Cheruvu S, Sammel N, Brew B, Otton J, Holloway CJ.

J Cardiovasc Comput Tomogr. 2016 Jul 29. pii: S1934-5925(16)30181-2. doi: 10.1016/j.jcct.2016.07.018. [Epub ahead of print]

PMID:
27519655
3.

Characterization of the Kynurenine Pathway in CD8+ Human Primary Monocyte-Derived Dendritic Cells.

Braidy N, Rossez H, Lim CK, Jugder BE, Brew BJ, Guillemin GJ.

Neurotox Res. 2016 Aug 10. [Epub ahead of print]

PMID:
27510585
4.

A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review.

Bloch M, Kamminga J, Jayewardene A, Bailey M, Carberry A, Vincent T, Quan D, Maruff P, Brew B, Cysique LA.

Clin Infect Dis. 2016 Sep 1;63(5):687-93. doi: 10.1093/cid/ciw399. Epub 2016 Jun 19.

PMID:
27325690
5.

Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.

Lee JM, Tan V, Lovejoy D, Braidy N, Rowe DB, Brew BJ, Guillemin GJ.

Neuropharmacology. 2016 Jun 3. pii: S0028-3908(16)30209-X. doi: 10.1016/j.neuropharm.2016.05.011. [Epub ahead of print] Review.

PMID:
27265569
6.

Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.

Walker S, Brew B.

J Clin Neurosci. 2016 Sep;31:217-8. doi: 10.1016/j.jocn.2016.03.001. Epub 2016 May 8.

PMID:
27168454
7.

Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.

Lovelace MD, Varney B, Sundaram G, Lennon MJ, Lim CK, Jacobs K, Guillemin GJ, Brew BJ.

Neuropharmacology. 2016 Mar 16. pii: S0028-3908(16)30096-X. doi: 10.1016/j.neuropharm.2016.03.024. [Epub ahead of print] Review.

PMID:
26995730
8.

Strategies to target HIV-1 in the central nervous system.

Gray LR, Brew BJ, Churchill MJ.

Curr Opin HIV AIDS. 2016 Jul;11(4):371-5. doi: 10.1097/COH.0000000000000278.

PMID:
26945147
9.

Short Communication: Do Cytomegalovirus Antibody Levels Associate with Age-Related Syndromes in HIV Patients Stable on Antiretroviral Therapy?

Brunt SJ, Cysique LA, Lee S, Burrows S, Brew BJ, Price P.

AIDS Res Hum Retroviruses. 2016 Jun;32(6):567-72. doi: 10.1089/AID.2015.0328. Epub 2016 Mar 16.

PMID:
26876416
10.

Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.

Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ.

AIDS. 2016 Feb 20;30(4):591-600. doi: 10.1097/QAD.0000000000000951.

PMID:
26825032
11.

Understanding and optimizing brain health in HIV now: protocol for a longitudinal cohort study with multiple randomized controlled trials.

Mayo NE, Brouillette MJ, Fellows LK; Positive Brain Health Now Investigators.

BMC Neurol. 2016 Jan 14;16:8. doi: 10.1186/s12883-016-0527-1.

12.

Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals.

Crossley KM, Agnihotri S, Chaganti J, Rodriguez ML, McNally LP, Venna N, Turbett SE, Gutman M, Morey A, Koralnik IJ, Brew BJ.

J Neurovirol. 2016 Aug;22(4):541-5. doi: 10.1007/s13365-015-0419-y. Epub 2016 Jan 4.

13.

Bcl11b: A New Piece to the Complex Puzzle of Amyotrophic Lateral Sclerosis Neuropathogenesis?

Lennon MJ, Jones SP, Lovelace MD, Guillemin GJ, Brew BJ.

Neurotox Res. 2016 Feb;29(2):201-7. doi: 10.1007/s12640-015-9573-5. Epub 2015 Nov 12.

PMID:
26563995
14.

Implementing an anti-smoking program in rural-remote communities: challenges and strategies.

Tall JA, Brew BK, Saurman E, Jones TC.

Rural Remote Health. 2015 Oct-Dec;15(4):3516. Epub 2015 Nov 4.

15.

The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults.

Cysique LA, Dermody N, Carr A, Brew BJ, Teesson M.

J Neurovirol. 2016 Feb;22(1):56-65. doi: 10.1007/s13365-015-0368-5. Epub 2015 Aug 25.

PMID:
26304840
16.

CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies.

Gray LR, Cowley D, Welsh C, Lu HK, Brew BJ, Lewin SR, Wesselingh SL, Gorry PR, Churchill MJ.

Mol Psychiatry. 2016 Apr;21(4):574-84. doi: 10.1038/mp.2015.111. Epub 2015 Aug 25.

17.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
18.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

19.

Myasthenia gravis exacerbation with low dose ocular botulinum toxin for epiphoria.

Watts J, Brew B, Tisch S.

J Clin Neurosci. 2015 Dec;22(12):1979-81. doi: 10.1016/j.jocn.2015.05.032. Epub 2015 Jul 15.

PMID:
26188667
20.

Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease.

Jones SP, Franco NF, Varney B, Sundaram G, Brown DA, de Bie J, Lim CK, Guillemin GJ, Brew BJ.

PLoS One. 2015 Jun 26;10(6):e0131389. doi: 10.1371/journal.pone.0131389. eCollection 2015.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk